On 20 November 2001, orphan designation (EU/3/01/067) was granted by the European Commission to Pharmion Ltd, United Kingdom, for thalidomide for the treatment of multiple myeloma.
The sponsorship was transferred to Celgene Europe Limited, United Kingdom, in November 2008.
Thalidomide has been authorised in the EU as Thalidomide Celgene since 16 April 2008.
|Disease / condition||
Treatment of multiple myeloma
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.